Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 29, 2021

Organicell reports positive data from Covid-19 therapeutic trial In India 

Organicell Regenerative Medicine has reported positive results from the trial of its acellular biologic therapeutic Zofin for treating moderate to severe Covid-19 patients in India. 

Organicell Regenerative Medicine has reported positive results from the trial of its acellular biologic therapeutic Zofin for treating patients with moderate to severe Covid-19 in India.

Data showed that the first ten subjects who received Zofin recovered from Covid-19 symptoms and were discharged from hospital.

Zofin is obtained from perinatal sources. It is manufactured to preserve naturally occurring microRNAs, without adding any other substance or diluent.

The therapeutic contains over 300 growth factors, cytokines, and chemokines, along with other extracellular vesicles/nanoparticles obtained from perinatal tissues.

This initial trial is being carried out in collaboration with Organicell’s partner, CWI India.

In February this year, the companies signed a product testing and distribution agreement to analyse the effects of Zofin on moderate to severe Covid-19 patients.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Organicell Regenerative Medicine CEO Albert Mitrani said: “The explosive spread of Covid-19 in India, and the lack of treatment that is available to help these millions of people is quite alarming and tragic.

“We are hopeful that Zofin can continue to help these patients, and we will do everything we can to expedite this process.

The trial will be expanded to include 65 subjects with moderate to severe Covid-19. They will receive treatment at various hospitals in India for the next several weeks, with completion expected by the end of June.

On obtaining positive results of the expanded trial, Organicell and CWI India plan to submit an application to the Indian Council for Medical Research seeking emergency use approval for using Zofin as a Covid-19 therapeutic.

Doctor Matthew Roshan of CWI India said: “We are very encouraged with the results shown by patients using Zofin and are hopeful that the remaining trial patients will show similar results.

“These trials could set the stage for a very quick emergency use approval to be able to use Zofin for all of our patients.”

Last week, Organicell concluded patient enrolment for its expanded access trial of Zofin to treat Covid-19.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy